Considering the potential and significant role of fisetin against human non‐small‐cell lung cancer (NSCLC) cells (A549) in dose‐dependent fashion, inhibition of cell proliferation, PI3K/Akt, and mTOR signaling, reduction in development of colonies, inhibition of phosphorylation (mTOR, Akt, eIF‐4E, p70S6K1, and 4E‐BP1), reduction in protein expression of PI3K (p85 and p110), and also suppression of the constituents of mTOR signaling complex (Raptor, Rictor, PRAS40, and GβL) were reported after fisetin administration. Here, RPS6KB1 is linked to non-small cell lung carcinoma.